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MLL1 belongs to the SET1 family of histone H3 lysine
4 (H3K4) methyltransferases, composed of MLL1–4 and
SETd1A/B.MLL1 translocations are present in acute leukemias,
and mutations in several family members are associated with
cancer and developmental disorders. MLL1 associates with a
subcomplex containing WDR5, RbBP5, ASH2L, and DPY-30
(WRAD), forming the MLL1 core complex required for H3K4
mono- and dimethylation and transcriptional activation. Core
complex assembly requires interaction ofWDR5with theMLL1
Win (WDR5 interaction) motif, which is conserved across the
SET1 family. Agents that mimic the SET1 family Win motif
inhibit the MLL1 core complex and have become an attractive
approach for targetingMLL1 in cancers. LikeMLL1, other SET1
family members interact with WRAD, but the roles of the Win
motif in complex assembly and enzymatic activity remain unex-
plored. Here, we show that theWinmotif is necessary for inter-
action of WDR5 with all members of the human SET1 family.
Mutation of the Win motif-WDR5 interface severely disrupts
assembly and activity of MLL1 and SETd1A complexes but only
modestly disrupts MLL2/4 and SETd1B complexes without sig-
nificantly altering enzymatic activity in vitro. Notably, in the
absence of WDR5, MLL3 interacts with RAD and shows
enhanced activity. To further probe the role of the Win motif-
WDR5 interaction, we designed a peptidomimetic that binds
WDR5 (Kd3 nM) and selectively inhibits activity of MLL1 and
SETd1A core complexes within the SET1 family. Our results
reveal that SET1 family complexes with the weakestWinmotif-
WDR5 interaction are more susceptible to Win motif-based
inhibitors.
Mixed Lineage Leukemia 1 (MLL1) protein is a member of
the SET1 (or MLL) family of histone methyltransferases. In
humans, this family consists of six members: MLL1–4,
SETd1A, and SETd1B (1–8). The SET1 family catalyzes meth-
ylation of histone 3 lysine 4 (H3K4),3 an epigenetic mark that is
associated with active transcription (9–12). The human SET1
family is composed of large proteins with several well charac-
terized functional domains involved in chromatin binding and
protein-protein interactions (13, 14) (Fig. 1A). Although some
of these domains differ among family members, all share a
C-terminal SET (suppressor of variegation, enhancer of Zeste,
trithorax) domain that confersH3K4methyltransferase activity
(15). Like many chromatin-modifying enzymes, the SET1 fam-
ily works as part of multiprotein complexes that contain bind-
ing partners involved in enzymatic regulation and gene target-
ing. Although the majority of isolated SET1 family SET
domains catalyze weak H3K4 monomethylation (H3K4me1),
enhanced methylation is observed in the context of a “core
complex” (16). The minimal core complex required for
enhanced methylation is composed of the SET1/MLL SET
domain and a subcomplex called WRAD (WD-40 repeat pro-
tein 5 (WDR5), retinoblastoma-binding protein 5 (RbBP5),
absent small homeotic 2-like (ASH2L), and dumpy-30 (DPY-
30)) (17–20). Interestingly, SET1 family core complexes prefer-
entially catalyze different levels of H3K4methylation in a man-
ner that correlates with their evolutionary lineage (16).
Whereas SETd1A/B core complexes catalyze mono-, di-, and
trimethylation of H3K4 (H3K4me1, H3K4me2, and H3K4me3,
respectively), the MLL1 and MLL4 (also known as MLL2) core
complexes predominantly catalyze mono- and dimethylation
(16). In contrast,MLL2 andMLL3 core complexes catalyze pre-
dominantlyH3K4monomethylation (16). In cells, different lev-
els of H3K4 methylation are localized to distinct genomic
regions and are associated with distinct functional outcomes
(21–23). Assembly of the MLL1 core complex requires a direct
interaction betweenMLL1 andWDR5, wherebyWDR5 acts to
stabilize the interaction between the MLL1 SET domain and
the RbBP5/ASH2L heterodimer (18, 24). The MLL1-WDR5
interaction occurs via the conserved Win (WDR5 interaction)
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motif (24), located 50 amino acids N-terminal from the SET
domain,where a conserved arginine,Arg-3765 (inMLL1), plays
a critical role inmaking contacts withWDR5 (19, 25).Mutation
of Arg-3765 leads to severe destabilization of MLL1 core com-
plex and loss of MLL1 H3K4 dimethyltransferase activity in
vitro (24, 26).
MLL1 regulates transcriptional activation of genes involved
in development, neurogenesis, and fetal and adult hematopoi-
esis (27–31), including several genes in the HOX cluster (32,
33). Misregulation ofHOX genes is commonly observed in leu-
kemias associated withMLL1 genetic rearrangements (34–37).
Indeed, the MLL1 gene is a frequent site of genetic rearrange-
ment and accounts for 70% of infant acute lymphocytic leu-
kemia and 10% of de novo acute myeloid leukemia (AML) in
adults (38). Most genetic rearrangements of MLL1 result in
translocations that fuse the N-terminal fragment of the MLL1
protein (lacking the SET domain) to one of70 known fusion
partners (39) (Fig. 1B). One such type of MLL1 fusion, MLL1-
AF9, exhibits a dominant gain-of-function phenotype that con-
tributes to AML leukemogenesis in mice (40). Mechanistic
studies show that the wild type allele is required for leukemo-
genesis (41), suggesting that molecules targeting the wild type
SETdomainmay be a useful strategy for treatment (42). Certain
MLL1 gene rearrangements result in aberrant MLL1 proteins
that retain the catalytic domain (Fig. 1C). For example, AF4
(ALL-1-fused gene on chromosome 4) and NEBL (nebulin)
have been reported to form fusions with theMLL1 C terminus;
such fusions have been associated with oncogenic roles in leu-
kemia (43–47). Additionally, internal partial tandem duplica-
tions (Fig. 1D), which result in duplication of an N-terminal
segment of MLL1 retaining the C-terminal SET domain, have
been described in10% of AML patients and have been shown
to play a dominant gain-of-function role in oncogenesis (48).
Thus, targeting wild type MLL1 is a tractable approach for
treating these types of cancers.
Since the first demonstration of inhibition of the MLL1 core
complex by a peptidomimetic that targets the Win motif-
WDR5 interaction (24), several related compounds have been
developed (42, 49–54), some of which have been shown to spe-
cifically reduce cancer cell growth and elicit genome wide
reprograming that is consistent with anMLL1 deletion pheno-
type (42, 54, 55). However, because theWin motif is conserved
among all six SET1 family members, it is unclear the extent to
which these changes are due to specific targeting of the MLL1
core complex over other SET1 family complexes. Indeed, the
role of the Win motif-WDR5 interaction in other SET1 family
complexes remains unexplored.
In this investigation, we characterized the roles of the Win
motif in core complex assembly and enzymatic activity for each
human SET1 family complex. We found that all SET1 family
members interact withWDR5 in aWinmotif-dependent man-
ner, but not all complexes are affected by disruption of the
interaction in a similar way. Loss of WDR5-Win motif interac-
tion severely destabilizes MLL1 and SETd1A complexes and
moderately destabilizesMLL2–4 complexes but does not affect
the stability of the MLL3 core complex. To further probe the
role of the WDR5-Win motif interaction among family mem-
bers, we designed a 6-residue Win motif peptidomimetic
(Win6mer) that binds to WDR5 with high affinity (Kd 3 nM)
and found that it inhibits MLL1 and SETd1A complexes but
does not inhibit MLL2–4 or SETd1B complexes. This work
reveals that the contributions of theWinmotif-WDR5 interac-
tion to complex assembly differ among the human SET1 family
members and that such differences can be exploited to alter the
enzymatic activities of a subset of SET1 family core complexes.
In addition, our results reveal that theMLL1 and SETd1A com-
plexes that bindWDR5 with the weakest affinity are most sen-
sitive to inhibition by molecules that mimic the Win motif.
Results
Characterization of the Contributions of the Win Motif to
Complex Assembly—The Win motif is a highly conserved
regionwithin the SET1 family and is composed of 6 key residues
located N-terminal to the catalytic domain (24, 25, 49, 56) (Fig.
2A). This region was previously identified as necessary for the
pairwise interaction of MLL1 with WDR5 (24, 25) and for the
FIGURE 1. Schematic of common outcomes of MLL1 genetic rearrange-
ments. A, domain map of full-length wild type MLL1 with the breakpoint
region denoted by an arrow. MLL1 contains many domains involved in bind-
ing chromatin (i.e. AT-Hooks, CxxC domains, PHD, and bromodomains) as
well as domains involved in mediating protein-protein interactions (i.e.
meninbindingdomain (MeninBD) and theWDR5 interaction (Win)motif). The
SET and post-SET domains are involved in catalysis. The WRAD subcomplex
interacts with the C terminus ofMLL1. B, themost common outcome ofMLL1
genetic rearrangements, which result in replacement of the C terminus of
MLL1 with one of70 known fusion partners (i.e. AF9, AF4, and ENL). In this
arrangement, the N terminus is retained, but the catalytic SET/post-SET
domain is lost. C, a rearrangement that results in the replacement of the N
terminus of MLL1 with a fusion partner (i.e. AF4). In this arrangement, the
N-terminal domains are lost, but the catalytic domain is retained.D, result of a
partial tandemduplication in which a segment of the N terminus (containing
the AT-Hooks and CxxC domain) is duplicated and inserted at the break point
region.
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assembly of the MLL1 core complex (24). However, unlike
MLL1,MLL3 does not require interactionwithWDR5 to stably
interact with RbBP5/ASH2L (16, 42, 57, 58). Furthermore, a
recent study suggested that SET1 family members, with the
exception of MLL1, do not require WDR5 to assemble a fully
functional core complex (57). These results raise questions
about the role of theWinmotif andwhy it is so highly conserved
among metazoan SET1 family enzymes. Thus, we set out to
further characterize the roles of the Win motif in SET1 family
core complex assembly.
To determine whether the Win motif is required for direct
interaction with WDR5, we first mutated the Win motif argi-
nine to alanine in each SET1 family member and purified each
recombinant protein as a GST fusion. We then compared the
ability of wild type and mutant SET1 family members to inter-
act with WDR5 using a GST pull-down assay (Fig. 2B). We
observed that all SET1 family members pulled down recombi-
nantWDR5 (lanes 1, 3, 5, 7, 9, and 11), whereas the controlGST
protein lacking a SET1 family member did not (lane 13). Con-
sistent with having the weakest Win motif-WDR5 interaction
(49), MLL1 pulled down the least amount of WDR5. In con-
trast, all SET1 familymembers containing amutatedWinmotif
did not pull down WDR5 (lanes 2, 4, 6, 8, 10, and 12). These
results suggest that all SET1 family members directly interact
with WDR5 in a Win motif-dependent manner.
We then investigated the impact of disruption ofWinmotif-
WDR5 interaction on SET1 family core complex stability. We
compared the ability of wild type and Win motif mutant SET1
family GST proteins to pull down endogenousWRAD compo-
nents from MCF-7 breast cancer cell extracts using GST pull-
down assays (Fig. 2C). Although all wild type SET1 family GST-
proteins were able to interact with endogenous WRAD
components (lanes 1, 3, 5, 7, 9, and 11), we noticed that mutant
SET1 family members differed in their ability to interact with
WRAD (lanes 2, 4, 6, 8, 10, and 12). Substitution of each Win
motif arginine with alanine resulted in disruption of the SET
domain-WDR5 interaction in all complexes, consistent with
the Win motif playing a role in direct interaction with WDR5.
In addition, all complexes, with the exception of theMLL3 core
complex, showed reduced interactions with RbBP5 and
ASH2L, but to varying degrees. Substitution of the Win motif
arginine in the MLL1 and SETd1A constructs nearly abolished
core complex assembly, whereas MLL2 and MLL4 showed
weak interactionswith RbBP5 andASH2L, respectively. Substi-
tution of theWin motif arginine in SETd1BR1748A pulled down
RbBP5 and ASH2L, but to a lesser degree compared with wild
type SETd1B (Fig. 2C, lanes 11 and 12). Whereas MLL3R4710A
showed a decreased interaction withWDR5, its ability to inter-
act with RbBP5/ASH2L components was similar to that of wild
type MLL3 (Fig. 2C, lanes 7 and 8), consistent with previous
FIGURE 2. TheWinmotif is required for interactionwithWDR5.A, sequence alignment of the human SET1 familyWinmotif generated using Clustal Omega
(90). The 6-residueWinmotif is highlighted in blue, and the conserved arginine is enclosed in a box. B, GST pull-down of wild type andWinmutant SET1 family
members with WDR5. Individual GST-tagged SET domains (wild type or mutant) were incubated with purified WDR5 and glutathione-coated agarose beads.
A Coomassie Blue-stained SDS-polyacrylamide gel of the pull-down fractions only is shown. GST was used as a negative control (lane 13), and a sample of
purifiedWDR5was run on the gel to compare themigration of pull-down bands (lane 15). C, comparison of wild type ormutant GST-SET domain pull-down of
WDR5, RbBP5, and ASH2L from MCF-7 cell extracts. WRA components were detected by Western blotting. The top panel shows a Ponceau S-stained PVDF
membrane, and the bottom panels show the immunoblots. D, comparison of wild type or Win motif mutant FLAG-tagged full-length SETd1A and SETd1B
co-immunoprecipitation with WDR5, RbBP5, ASH2L, CFP1, WDR82, and HCF1 from stably transfected T-REx HEK293 cells.
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findings (16, 57, 58). These results demonstrate the importance
of the Win motif for the interaction of WDR5 with each SET1
family core complex but also reveal differences in the role that
WDR5 plays in complex stability in vitro.
To determine whether the same differences are observed in
cells, we selected the closely related SETd1A and SETd1B fam-
ily members to further probe the role of the WDR5-Win motif
interaction inmammalian cells.We stably transfected HEK293
cells with full-length human SETd1A and SETd1B constructs
and compared the ability of wild type and Win motif mutant
variants to co-immunoprecipitate endogenousWRAD compo-
nents. Similar to the results of the GST pull-down assays, we
found that substitution of the Win motif arginine with alanine
abolished the interaction with WDR5 in both complexes (Fig.
2D, compare lanes 3 and 4 and lanes 5 and 6, respectively). In
addition, loss of theWDR5-Winmotif interaction severely dis-
rupts SETd1A interactionwith RbBP5 andASH2L, whereas the
same interactions were only modestly reduced when the
SETd1BWinmotif arginine was replaced with alanine. Despite
these changes, substitution of the Win motif arginine with ala-
nine did not significantly affect the ability of either protein to
co-immunoprecipitate with SETd1A/B-interacting proteins
CFP1, WDR82, and HCF1. These data confirm the results
obtained from the GST pull-down experiments and suggest
that amino acid variation between SETd1A and SETd1B pro-
teins accounts for the ability of RbBP5/ASH2L to interact with
the SET domain in the absence of WDR5.
Altogether, these results demonstrate that all SET1 family
members require the Win motif for interaction with WDR5.
Moreover, whereas the Win motif-WDR5 interaction is not
required for the interaction betweenMLL3 andRbBP5/ASH2L,
it is required for the stability of the MLL1, MLL2, MLL4,
SETd1A, and SETd1B core complexes, but to different degrees.
Contributions of theWinMotif to SET1FamilyHistoneMeth-
yltransferase Activity—We previously reported that substitu-
tion of theMLL1Winmotif arginine with alanine reduces core
complex H3K4 dimethylation activity (24), whereas a similar
substitution in the MLL3 Win motif increases core complex
H3K4 monomethylation activity (16, 58). The contributions of
the Win motif to the methyltransferase activity of the other
SET1 family core complexes remain to be explored.
To address this knowledge gap, we compared the enzymatic
activity of core complexes assembled with wild type or with
Win motif mutant SET1 family proteins using histone H3 pep-
tides (residues 1–20) that were unmodified (H3K4me0) or were
monomethylated (H3K4me1) or dimethylated (H3K4me2) at
lysine 4 as substrates. Reaction mixtures were separated by
SDS-PAGE and imaged by fluorography (Fig. 3A). Quantitative
measurements were obtained by excising peptide bands from
the gels for liquid scintillation counting (Fig. 3B), as described
under “Experimental Procedures.” The results upon mutation
of each Win motif are highly similar to those of our previously
reported assays with wild type complexes in the absence of
WDR5 (16). When each complex was incubated with methyl-
3H-labeled S-adenosylmethionine ([3H]AdoMet) and the
H3K4me0 peptide, we observed that methylation levels were
similar between wild type and Win motif variants, with the
exception of the mutant MLL3 core complex, which showed
2-fold more activity than the wild type MLL3 core complex
(Fig. 3,A (lanes 4 and 11) andB (top)). These results suggest that
despite the substitution of each Win motif arginine with ala-
nine, the proteins are still folded and enzymatically active.
In contrast, when H3K4me1 and H3K4me2 peptides were
used as substrates, MLL1 and SETd1A complexes showed sig-
nificant differences in activity betweenwild type andWinmotif
variants. Complexes assembled with MLL1 and SETd1A Win
motif variants showed at least a 2-fold reduction in activity
compared with their wild type counterparts (Fig. 3,A (compare
lanes 1 and 8 and lanes 5 and 12) and B (middle and bottom
panels)). Conversely, complexes assembled with MLL4 and
SETd1BWinmotif variants showed similar amounts of activity
compared with that of their wild type counterparts (Fig. 3, A
(compare lanes 2 and 9 and lanes 6 and 13) and B (middle)).
Interestingly, whereas the wild type MLL2 core complex cata-
lyzes trace amounts of H3K4 dimethylation above background
in vitro (Fig. 3, A (lane 3) and B), we observed a 2-fold increase
in this activity with theMLL2Winmotif variant (Fig. 3,A (lane
10) and B). These results are similar to the stimulation of the
monomethylation activity of MLL3 and MLL2 core complexes
in the absence of WDR5 (16). In contrast, both wild type and
Win motif mutant MLL3 core complexes showed negligible
activity with H3K4me1/2 substrates.
Together, these results demonstrate that the Win motif is
required for the full methyltransferase activity of MLL1 and
SETd1A complexes, consistent with the central role of WDR5
in their assembly (16). In contrast, despite the moderate desta-
bilization of MLL2, MLL4, and SETd1B core complexes upon
mutation of the Win motif, the complexes retain a sufficient
amount of interaction with the RbBP5/ASH2L heterodimer to
allow nearly full enzymatic activity in the absence of the Win
motif-WDR5 interaction under these conditions. These results
suggest that targeting theWDR5-Winmotif interactionmay be
a useful strategy for selective inhibition of the MLL1 and
SETd1A complexes.
Structure-based Design and Characterization of a New High
Affinity Win Motif Peptidomimetic—Our data suggest that
SET1 family core complex stability and enzymatic activity are
regulated byWinmotif-WDR5 interaction to different extents.
Thus, molecules designed to disrupt this interface are expected
to mainly affect MLL1 and SET1d1A core complexes because
they more strongly rely on WDR5 for assembly and function.
To test this hypothesis, we designed and characterized a new
Win motif peptidomimetic and tested its inhibition properties
against all six human SET1 family core complexes. We have
previously shown that 14-residue peptides derived from the
naturally occurringWinmotif sequences of SET1 family mem-
bers inhibit the dimethylation activity of the MLL1 core com-
plex (49). Structure-function analyses show that each peptide
binds to WDR5 in a similar manner but with a wide range of
affinities (50–2800 nM) (49) (Table 1). In some peptides with
the highest affinity forWDR5,we found an additional hydrogen
bond between the fourth residue C-terminal to the Win motif
arginine and the conserved Asp-172 in WDR5 that was absent
in complexes with lower affinities (49). In addition, we found
that valine in the P3 position (3 residues C-terminal to the
crucial arginine residue, denoted as P0) is expected to promote
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a conformation that places a tyrosine at the P4 position in an
optimal orientation to form this hydrogen bond. Therefore, we
synthesized a 6-residue peptidomimetic that was designed to
combine the best features of high affinity binding peptides
while minimizing its overall size. The sequence contained
amino acid residues ARTEVY and was acetylated on the N ter-
minus and amidated on the C terminus to promote stability
(Ac-ARTEVY-NH2). This peptidomimetic is referred to here as
“Win6mer.” Thermodynamic bindingmeasurements using iso-
thermal titration calorimetry (ITC) revealed that Win6mer
binds toWDR5with aKd of 2.9 nM (1.7–4.2 nM, 95% confidence
interval) (Fig. 4A), which is an 18-fold increase in binding
affinity over the best naturally occurring Win motif sequence
(Table 1).
To determine whether Win6mer binds WDR5 in a similar
manner to other Win motif peptides, we determined the co-
crystal structure of the Win6mer-WDR5 complex at 2.0 Å res-
olution (Fig. 4, B–E). Data collection and refinement statistics
are summarized in Table 2. The overall structure ofWDR5was
FIGURE3.Substitutionof theWinmotif argininealtersSET1corecomplex-catalyzedH3K4methyltransferaseactivity invitro.A, samplegel showing the
comparison of core complex methyltransferase activities among SET1 family members (wild type andmutant) in the presence of WRAD. The top panels show
Coomassie Blue-stained SDS-polyacrylamidegels, and the bottompanels show 3H-methyl incorporation after 4 h of exposure as detectedby fluorography. The
control lane shows the activity of theMLL1WT SET domainwith 100MH3K4me0 peptide, which is included on each gel. B, quantification of radioactivity from
excised histone H3 bands by LSC. Data are normalized to the activity level of the control lane on each gel. Error bars, S.E. of measurement among three
independent experiments.
TABLE 1
Binding affinities ofWinmotif-basedMLL1 inhibitors towardWDR5as
determined by isothermal titration calorimetry
Win motif mimetic Dissociation constant Kd S.D.
nM
MLL1a (49) 2762 338
MLL4a (49) 88 6
MLL2a (49) 75 5
MLL3a (49) 54 5
SETd1Aa (49) 541 46
SETd1Ba (49) 103 14
Win6mer 2.9 (1.7–4.2)b
WDR5-0103 (53) 450 0.02
OICR-9429 (50) 93 28
a Peptides derived from the native Win motif sequence of each SET1 family
member.
b 95% confidence interval of the determined dissociation constant.
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highly similar to previously reported structures (25, 56, 59–62),
consisting of a seven-blade -propeller with a cavity through
the center of the protein (Fig. 4, D and E). This central cavity is
denoted as the “Win motif-binding pocket” because previous
co-crystal structures of WDR5 with SET1 family Win motif
peptides have shown it to be the binding site of the conserved
Winmotif arginine (25, 49, 56, 62). A simulated annealing Fo
Fc omit map contoured at 3 unambiguously shows density for
the peptide in the co-crystal structure in theWinmotif-binding
pocket (Fig. 4B), indicating that it does indeed bind in amanner
similar to that of other Win motif peptides.
Win6mer binds toWDR5 in a 310-helical conformation with
the conserved arginine (P0) inserted into the Win motif-bind-
ing pocket (Fig. 4, B and C). The 310-helical conformation is
stabilized by two sets of intrapeptide i to i3 hydrogen bonds:
one between the acetyl-capping group at the N terminus of the
peptide and the main and side chain of the P1 threonine (Fig.
4C) and the other between the main chain of the P1 alanine
and the main chain of the P2 glutamate. The P1 alanine
amino group also hydrogen-bonds with Asp-107 of WDR5,
whereas the main chain of the P2 glutamate hydrogen-bonds
with the main chain of the P0 arginine (Fig. 4C). The side chain
of the P0 arginine showed extensive hydrogen bonds within the
Winmotif-binding pocket ofWDR5. Furthermore, the position
of the P0 arginine guanidinium is sandwiched between two
conserved phenylalanines (Phe-133 and -263) in WDR5 and is
probably stabilized by cation- interactions. This feature is
nearly identical to all previously published Win motif peptide-
WDR5 structures (25, 49, 56, 62). The P3 valine side chain is
solvent-exposed and orients the P4 tyrosine side chain in a
region in WDR5 known as the A pocket (Fig. 4E) (49). The A
pocket inWDR5 contains residues Tyr-191, Pro-173, Phe-149,
and Asp-172. As predicted, the P4 tyrosine hydrogen bonds
with the side chain of Asp-172 from WDR5 (Fig. 4E). Overall,
the structure reveals that all 6 residues inWin6mer play impor-
tant roles in binding WDR5, which probably explains its
improved binding affinity for WDR5 when compared with the
previous SET1 family Win motif peptides.
Win6merAlters theMethyltransferase Activities of a Subset of
SET1 Family Core Complexes—Given that different SET1 fam-
ily members differ in their requirement for the Win motif-
WDR5 interaction for complex assembly and function, we
hypothesized that treatment of the SET1 family of core com-
plexeswithWin6merwould result inmethyltransferase activity
patterns thatmimic loss ofWDR5ormutation of theWinmotif
(Fig. 3). To test this hypothesis, we compared the methyltrans-
ferase activity of SET1 core complexes that were treated with
increasing concentrations of Win6mer with that of untreated
complexes using radiometric assays. When H3K4me0 was the
substrate, we observed that Win6mer reduced the activity of
the MLL1 and SETd1A core complexes in a dose-dependent
manner (Fig. 5A), whereas complexes assembled withMLL2–4
and SETd1B were uninhibited. The Win6mer peptide shows
similar inhibition efficiency for MLL1 and SETd1A core com-
FIGURE 4.Co-crystal structure ofWin6mer andWDR5at 2.0Å resolution.A, thermodynamic characterization of theWDR5-Win6mer interaction by ITC. The
binding affinityKd is reportedwith a confidence interval of 2or 95%.B, simulated annealing Fo Fcomitmap contoured at 3unambiguously shows electron
density corresponding to the Win6mer peptide. C, intra-Win6mer and Win6mer-WDR5 bonding network. Hydrogen bonds are represented by dashed lines.
Participating residues are labeled indark yellow (Win6mer) andpurple (WDR5). PositionP0 corresponds to the conservedarginine residue. Positions P andP
correspond to residuesN- andC-terminal of P0, respectively.D, cut-awayof a surface renditionof theWin6mer/WDR5 structure.WDR5 is shown in gray, and the
Win6mer peptide is shown in yellow. The conserved arginine is inserted into the Win motif binding pocket in WDR5. E, overlay of the MLL1Win motif peptide
(green) (Protein Data Bank code 3EG6 (56)) and Win6mer peptide (yellow). The conserved arginines are oriented in a highly similar manner within the central
cavity in WDR5 (magenta). The P4 residue in both peptides binds the A-pocket (orange dashed circle) and not the B-pocket (blue dashed pocket) (49).
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plexes, with average IC50 values of 2.2 and 2.5 M, respectively
(2 M enzyme complex assayed) (Table 3). Similar inhibition
patterns were observed when the H3K4me1 and H3K4me2
peptides were used as substrates (Fig. 5, B and C, respectively).
Together, these results show thatMLL1 andSETd1Acore com-
plexes are specifically inhibited by the Win6mer peptidomi-
metic that targets the Win motif-WDR5 interaction.
These results raise the question of why MLL1 and SETd1A
complexes are specifically targeted over complexes assembled
with MLL2–4 and SETd1B. We hypothesize that two key vari-
ables account for the differences: 1) affinity of theWinmotif for
WDR5 and 2) affinity of the RbBP5/ASH2L heterodimer for the
SET domain in the absence of WDR5, which influences overall
complex stability.Wepreviously found thatWinmotif peptides
derived from the human MLL1 and SETd1A sequences bind
WDR5 with significantly weaker affinity (Kd 2.8 and 0.5 M,
respectively) compared with that of peptides derived from
human MLL2–4 and SETd1B sequences (Kd  0.05–0.1 M)
(Table 1) (49). These data suggest that the Win motif-WDR5
interaction ismore easily disrupted inMLL1 and SETd1A com-
plexes comparedwith the other complexes. Consistentwith the
second hypothesis, we previously found that complexes assem-
bled with MLL1 and SETd1A rely more heavily on WDR5 for
interactionwith the RbBP5/ASH2Lheterodimer than the other
complexes for enzymatic activity (16). Indeed, we found in this
investigation that titration of WDR5 into the MLL1-RAD and
SETd1A-RAD complexes showed that stoichiometric amounts
of WDR5 are required for full activity (Fig. 5, E and F).
Together, these results suggest thatWDR5 plays amore crucial
role in overall stability of the MLL1 and SETd1A core com-
plexes and are therefore more susceptible to inhibition by mol-
ecules that target the WDR5-Win motif interaction. Last, our
data suggest that theMLL1 and SETd1A complexes have lower
overall stabilities compared with other complexes. Consistent
with this hypothesis, we observed that the IC50 values for the
Win6mer were highly dependent on enzyme complex concen-
tration.We found thatWin6mer inhibitedMLL1 core complex
with IC50 values of 2.2, 0.8, and 0.3 M when 1.8, 1, and 0.5 M
of enzyme complex were assayed, respectively (Fig. 5D). Lower
concentrations of complex shift the equilibrium toward the
unassembled complex, making it easier to gain access to the
Win motif-binding pocket on WDR5. Overall, these results
suggest that Win6mer preferentially inhibits the methylation
activities of MLL1 and SETd1A core complexes due to lower
overall complex stability and easier access to the Win motif-
binding pocket on WDR5.
The Win6mer Peptide Disrupts MLL1 and SETd1A Core
Complex Assembly but Does Not Inhibit Isolated SET Domain
Activity—Activity assays show thatWin6mer selectively down-
regulates the methyltransferase activity of MLL1 and SETd1A
core complexes. This inhibition is most likely due to disruption
of the Win motif-WDR5 interaction and destabilization of
complex assembly.However, the amino acid sequences of SET1
familyWinmotifs andWin6mer peptides are somewhat similar
to that of the histone H3 N-terminal tail (24), a SET domain
substrate. Thus, it is also possible that theWin6mermay inhibit
core complex activity by binding to the SET domain active site.
To distinguish between these potential mechanisms of core
complex inhibition, we assessed the effects of Win6mer treat-
ment on isolated SET domain activity and on SET1 family core
complex assembly.
First, we tested whetherWin6mer inhibits the isolated SET1
family catalytic domains. For this purpose, we treated isolated
SET domains with 100 M Win6mer and assessed their enzy-
matic activity towardH3 via a radiometric assay.We found that
Win6mer treatment did not affect the intrinsic monomethyl-
transferase activity of SET1 family members (Fig. 6, A and B).
This suggests that Win6mer does not bind to the SET domain
and does not interfere with SET domain-catalyzed H3K4
methylation.
Next, we tested whether Win6mer inhibits core complex
activity via disruption or destabilization of the core complex
assembly. We compared the ability of SET1 family members to
interact with endogenous WRAD components from MCF-7
cell extracts in the presence and absence of Win6mer by GST
pull-down experiments. Treatment with Win6mer greatly
reduced the ability of all six SET1 family members to interact
with endogenous WDR5 compared with untreated samples
(Fig. 6C). However, we found thatWin6mer treatment resulted
in a nearly total loss of RbBP5/ASH2L interaction only with
MLL1 and SETd1A complexes (Fig. 6C, compare lanes 1 and 2
and lanes 9 and 10). Other SET1 family members (MLL2,
MLL3,MLL4, and SETd1B) showed only amodest reduction in
RbBP5/ASH2L binding upon Win6mer treatment when com-
pared with the untreated set (Fig. 6C, lanes 3–8, 11, and 12).
TABLE 2




a, b, c (Å) 74.9, 74.9, 93.5
, ,  (degrees) 90.0, 90.0, 120.0
X-ray source MacCHESS F1
Wavelength (Å) 0.977
Resolution (Å) 50.0–2.00 (2.07–2.00)
Total reflections 330,393
Unique reflections 39482
Completeness (%) 100.0 (100.0)
Rsym (%) 11.7 (56.8)
I/(I)	 32.2 (5.0)
Multiplicity 8.4 (7.9)
Wilson B factor (Å2) 26.1
Refinement
Resolution (Å) 37.95–2.00 (2.05–2.00)
R factor (%) 21.4 (30.4)
Free R factor (%) 24.3 (36.3)
Free R reflections (%) 4.9
No. of free R reflections 1955
Molecules in asymmetric unit 2
Residue range built A/31–334, B/32–334, C/1–6, D/1–6
No. of non-hydrogen atoms 5143
No. of water molecules 272
Model quality
Root mean square deviations
Bond lengths (Å) 0.003
Bond angles (degrees) 0.884




Chain C (Win6mer) 26.6
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These results are largely consistent with those observed upon
mutation of each SET1 familyWin motif (Fig. 2C) and confirm
that MLL1 and SETd1A core complexes are more sensitive to
complex destabilization by inhibition of the WDR5-Win motif
interaction. These results also reveal that the mechanism of
inhibition byWin6mer is due toMLL1 and SETd1A core com-
FIGURE 5. Inhibition of SET1 family core complex activity byWin6mer. The activity of SET1 family core complexes upon titration ofWin6mer was assessed
via scintillation proximity assay. SET1 family core complexes were assayed according to their substrate specificity as follows (16). A, all SET1 core complexes
were assayed for monomethylation (H3K4me0 substrate). B, MLL1, MLL4, SETd1A, and SETd1B core complexes were assayed for dimethylation (H3K4me1
substrate). C, SETd1A and SETd1B core complexes were assayed for trimethylation (H3K4me2 substrate). IC50 values are reported on Table 3. D, efficiency of
MLL1core complex inhibitionbyWin6mer is dependentonenzymeconcentration. IC50 values are shown in the inset. Activitydata for eachSET1 familymember
were normalized to the activity of uninhibited core complex. Data were fit to a dose response with variable slope equation (Equation 1). Shown is monom-
ethyltransferase activity of MLL1-RAD (E) and SETd1A-RAD (F) upon titration of WDR5. Activity data were normalized to the activity of MLL1-RAD or SETd1A-
RAD in the absence of WDR5. Data were fit to a dose response with variable slope equation (Equation 1). Error bars, S.E. of measurement between two
independent experiments.
TABLE 3
Win6mer inhibition efficiency of SET1 family core complexes
Core complex
Inhibition efficiency, IC50 (95% confidence interval)
H3K4me0 H3K4me1 H3K4me2
M
MLL1 2.3 (1.6–3.3) 2.2 (1.7–2.8) NAa
MLL4 —b — NA
MLL2 — NA NA
MLL3 — NA NA
SETd1A 3.2 (2.0–5.2) 2.9 (1.7–5.1) 2.4 (1.4–4.1)
SETd1B — — —
aNA, not applicable due to substrate specificity (16).
b—, not inhibited at tested Win6mer concentrations.
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plex destabilization and not competition with histone H3 for
binding to the SET domain.
Discussion
WDR5 was first associated with accelerating osteogenic dif-
ferentiation (63) before its identification as a member of the
SET1 family core complexes (8, 64).WDR5 is required tomain-
tainH3K4methylation levels in yeast and in vertebrates (10, 18,
65–68), but the molecular mechanisms involved are debatable.
Previous studies implicate WDR5 in bridging interactions
between SET domain and the RbBP5/ASH2L heterodimer
within the MLL1 core complex (18, 24), but other studies sug-
gest that it has additional roles in gene targeting. For example,
WDR5 has been shown to be preferentially pulled down by
H3K4me2 peptides, leading to the hypothesis that it acts as a
histone effector domain that recruits the MLL1 core complex
to chromatin to catalyze H3K4 trimethylation (66). However,
crystal structures ofWDR5 bound toH3K4 peptides reveal that
it specifically recognizes Arg-2 instead of Lys-4 of histone H3
(59–61, 69), leading to the hypothesis that WDR5 functions as
a presenter domain that positions lysine 4 for methylation by
the SET domain active site (60). Missing is an unambiguous
demonstration that the MLL1 core complex can be pulled
down in a manner that depends on the Arg-2 binding site of
WDR5. In an effort to better understand the role of WDR5, we
and others have found that WDR5 recognizes Arg-3765 of the
FIGURE 6. The Win6mer peptide interferes with core complex assembly for a subset of SET1 family members. A, representative gel of a comparison of
monomethyltransferase activities among isolated SET1 family SET domains in the absence of WRAD treated with (100M) or without Win6mer. The top panel
shows the Coomassie Blue-stained SDS-polyacrylamide gel, and the bottom panel shows 3H-methyl incorporation into H3K4 peptide after 4 h of exposure, as
detected by fluorography. The control lane shows the activity of the MLL1WT SET domain on 100 M H3K4me0 peptide. B, quantification of radioactivity from
excised histoneH3 peptide bands by LSC. Data are normalized to the activity level of the control lane on each gel. Error bars, S.E. ofmeasurement among three
independent experiments. C, comparison of core complex assembly by SET1 family members from pull-down experiments from MCF-7 cell extracts in the
presence () (10 M) or absence () of Win6mer. Individual GST-tagged SET domains were incubated with cell extracts and pulled down with glutathione-
agarose beads.WRA componentswere detected byWestern blotting. The top panel shows a Ponceau S-stained PVDFmembrane, and the bottompanels show
the immunoblots. GST (not treated with Win6mer) was used as a negative control (lane 14).
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MLL1 Win motif using the same site that it uses for binding
H3R2 (24, 25, 56), indicating that WDR5 cannot simultane-
ously interact with MLL1 and histone H3 when it is assembled
into the MLL1 core complex. These results argue against the
effector or presenter domain hypotheses and suggest that
WDR5 functions mainly as a bridge for stabilizing the interac-
tion between MLL1 and the RbBP5/ASH2L heterodimer.
Because the Win motif is highly conserved (24), it has been
hypothesized that WDR5 plays a similar role in all six human
SET1 family complexes.
In this investigation, we show that all six human SET1 family
members indeed require the Win motif for interaction with
WDR5. However, we also observed differences in the role of
WDR5 in stabilizing complex assembly and enzymatic activity,
suggesting that the Win motif-WDR5 interaction may be con-
served for additional functions. In particular, mutation of the
Winmotif severely disrupts assembly and enzymatic activity of
MLL1 and SETd1A complexes but only modestly disrupts
assembly of MLL2/4 and SETd1B complexes, without signifi-
cant changes in their activity. In contrast, disruption of theWin
motif-WDR5 interface does not affect MLL3 core complex
assembly but enhances its enzymatic activity, consistent with
previous work (16, 58). These results raise the question of why
theWinmotif is highly conserved amongmetazoan SET1 fam-
ily members. Our results suggest that WDR5 plays, to varying
degrees, a role in complex stabilization for most SET1 family
members. Alternatively, it is possible that the Win motif-
WDR5 interaction has been retained throughout evolution for
additional roles, such as for interactionwith other proteins or in
gene targeting. Indeed, WDR5 interacts with several transcrip-
tion factors (e.g.OCT4 and MYC) (70, 71), with long non-cod-
ing RNAs (e.g. HOTTIP) (72) and PIWI-interacting RNAs (e.g.
GAS5) (73), and has been implicated in recruiting the MLL1
core complex to specific genomic loci.
Our results also reveal differences in SET1 family SET
domains that allow varying degrees of interaction with RbBP5/
ASH2L in the absence of WDR5. MLL1 and SETd1A both
require WDR5 for complex assembly but come from separate
phylogenetic subclades (16) within the SET1 family, each con-
taining members that do not rely as much on WDR5 for inter-
action with RbBP5/ASH2L. This observation suggests that the
requirement of WDR5 for complex assembly may be a conver-
gent property within each subclade, which raises the possibility
that differentmechanismsmay be involved. For example, it was
recently shown that substituting MLL1 residues at both posi-
tions Asn-3861 and Gln-3867 with the corresponding amino
acids in theMLL2 andMLL3 SET domains results in increased
interaction with an RbBP5 peptide/ASH2L SPRY domain het-
erodimer and increased core complex activity in the absence of
WDR5 (57). However, variation in the same amino acid posi-
tions does not explain the differences in the requirement for
WDR5 in the assembly of the human SETd1A and SETd1B
complexes, because the amino acids are highly similar in those
positions. These results suggest that variation in other amino
acid positions accounts for the differences in the requirement
for WDR5 in human SETd1A and SETd1B complexes.
Although it was previously suggested that a 4-residue basic
patch in yeast Set1 and human SETd1A SET domains stabilizes
interaction with RbBP5/ASH2L in the absence of WDR5 (74),
this basic patch is conserved in both SETd1A and SETd1B, but
not in MLL1–4, and therefore cannot account for the differ-
ences. Likewise, we previously reported the identification of a
common cluster of Kabuki syndrome missense variants that
disrupt interaction between the SET domain and RbBP5/
ASH2L in a WDR5-independent manner (26). However, the
amino acids in this Kabuki interaction surface are conserved in
all SET1 family SET domains and therefore cannot explain the
variation in complex stability among family members. Identifi-
cation of the amino acid residues that do account for those
differences in future studies may allow development of inhibi-
tors that more specifically target unique protein-protein inter-
actions in the MLL1 or SETd1A core complexes.
Our observation that MLL1 and SETd1A require WDR5 for
enzymatic activity and complex assembly contrasts with previ-
ous reports suggesting that only MLL1 requires WDR5 for
these purposes (42, 57). A possible reason for this discrepancy is
that in previous studies, enzymatic activity was measured with
only the H3K4me0 substrate using an assay that does not dis-
tinguish among different methylation states. Indeed, we
observed little differences in activity among family members
withWinmotifmutants in assays using theH3K4me0 substrate
with a relatively long incubation period (Fig. 3). Assays con-
ducted with shorter incubation periods within the linear range
do show that both MLL1 and SETd1A, but not MLL2–4 and
SETd1B core complexes, are sensitive to Win6mer inhibition
when H3K4me0 is used as a substrate (Fig. 5A). However, rates
of H3K4 di- and trimethylation are most affected by disruption
of the Win motif-WDR5 interaction in the human MLL1 and
SETd1A complexes, respectively, because both show signifi-
cantly reduced activity upon mutation of the Win motif or
Win6mer treatment under both assay conditions (Figs. 3 and 5
(B andC)). The results emphasize the importance of examining
the impact of SET1 family inhibitors on eachH3K4methylation
state.
In addition, a recent report suggests that all SET1 family
members, with the exception of MLL1, interact with RbBP5/
ASH2L in the absence of WDR5 (42, 57). This contrasts with
the results of this study, which show that all human SET1 family
core complexes, with the exception of theMLL3 core complex,
are destabilized to varying degrees in the absence of WDR5.
This discrepancy is probably due to differences in the strin-
gency in binding andwash conditions in GST pull-down exper-
iments. Indeed, it was previously shown that both MLL1 and
SETd1A, but not MLL2–4 and SETd1B, lose interaction with
RbBP5/ASH2L when higher ionic strength wash conditions
(300 mM NaCl) are used (57) as in this study.
Although a previous report suggests that targeting the Win
motif-WDR5 interaction inhibits only the MLL1 core complex
(42), several independent lines of evidence suggest that both
MLL1 and SETd1A complexes are inhibited. A peptidomimetic
called MM-401 was shown to cause G1/S cell cycle arrest,
reduceH3K4 trimethylation levels, and alter gene expression in
a manner that resembles in part the phenotype of the MLL1
knock-out (42). Although the effect of MM-401 on the H3K4
methylation activity of the human SETd1A complex was
unclear in that study (42), a more recent investigation showed
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that a similar phenotype is observed in SETd1A knock-out
mouse embryonic stem cells (75). In addition, we have previ-
ously shown that the MLL1 core complex catalyzes predomi-
nantly H3K4 mono- and dimethylation, whereas the SETd1A
core complex catalyzes H3K4mono-, di-, and trimethylation in
in vitro assays, posing the possibility that inhibition of SETd1A
accounts for loss of H3K4 trimethylation in response to
MM-401. This is consistent with reports suggesting that
SETd1A and SETd1B account for the bulk of H3K4 trimethyl-
ation in cells (76, 77). However, because both complexes con-
tribute to the cellular pool ofH3K4dimethylation, the substrate
for the trimethylation reaction, it is possible that inhibition of
both enzyme complexes contributes to the overall loss of H3K4
trimethylation in cells.
Despite conservation of the Win motif, WDR5 recognizes
SET1 family Win motifs with significantly different affinities
(49), suggesting a therapeutic window in which to selectively
target individual family members. In this work, we utilized a
new Win motif peptidomimetic (Win6mer) that exploits a
unique set of hydrogen bonds that significantly increases affin-
ity for WDR5 compared with other inhibitors. Indeed,
Win6mer has the highest reported affinity for the Win motif-
binding site onWDR5 when comparing dissociation constants
among inhibitors obtained by a direct binding ITC assay (Table
1). Although it is unclear whether Win6mer can cross cell
membranes, it has proven to be a useful tool in dissectingmech-
anistic differences in the assembly of SET1 family core com-
plexes and should serve as the basis for the development of the
next round of Win motif inhibitors with improved specificity
and pharmacodynamic properties.
We propose that the basis of Win6mer selectivity for MLL1
and SETd1A core complexes lies in the disruption of the Win
motif-WDR5 interface, which is required for stabilizing con-
tacts with the RbBP5/ASH2L heterodimer (Fig. 7). MLL1 and
SETd1A share the properties that they have the lowest binding
affinities for WDR5 (49) and for the RbBP5/ASH2L het-
erodimer, the combination of whichmakes them susceptible to
inhibition of the Win motif-WDR5 interface. Uncoupling this
combination, through amino acid variation that increases affin-
ity either for WDR5 or for the RbBP5/ASH2L heterodimer,
renders those complexes less susceptible to inhibition. This
explains why the MLL2–4 and SETd1B can retain catalytic
activity in the presence of the Win6mer, because they have
higher binding affinities for WDR5 or they retain to varying
degrees the ability to interact with RbBP5/ASH2L. It is likely
that the same mechanism accounts for the inhibition prop-




WDR5 antibody was obtained from Abcam (ab22512).
RbBP5 and ASH2L antibodies were obtained from Bethyl
(A300-109A and A300-498A, respectively). An HRP-conju-
gated donkey anti-rabbit antibody was obtained from GE
Healthcare. Anti-FLAG M2 agarose beads and anti-FLAG
(mouse monoclonal M2) antibody were obtained from Sigma.
Custom antisera directed against WDR5, CFP1, and WDR82
were prepared as described (1). HCF1 antiserum was a gener-
ous gift from Dr. Winship Herr.
HistoneH3peptideswere synthesized byGenScript and con-
tained residues 1–20 followed by GGK-biotin and were either
unmodified (H3K4me0), monomethylated (H3K4me1), or
dimethylated (H3K4me2) at H3K4. All peptides were purified
to95% purity. All H3K4 peptides weremodified by amidation
of the C terminus. The 6-mer Win motif peptidomimetic
(Win6mer), of sequenceAc-ARTEVY-NH2,was synthesized by
GenScript. Win6mer was acetylated on the N terminus and
amidated on the C terminus to remove charge and improve
peptide stability.MCF-7 cell extracts were obtained from Santa
Cruz Biotechnology, Inc. (sc-24793).
Protein Expression/Purification
Human SET1 family Win-SET cDNAs encoding residues
MLL1(3745–3969) (UniProtKB ID Q03164), MLL2(5319–
5537) (UniProtKB ID O14686), MLL3(4689–4911) (Uni-
FIGURE 7.Model for down-regulation ofMLL1 and SETd1A core complex activity byWin6mer. A, MLL1 and SETd1A SET domains require interactionwith
WDR5 for stabilizing assemblywith the components of RAD. Like all SET1 familymembers,MLL1 andSETd1Autilize theWinmotif to interactwithWDR5. Stably
assembledMLL1 and SETd1A core complexes exhibit full H3K4methyltransferase activity. B, treatmentwithWin6mer, aWinmotif peptidomimetic, competes
withMLL1 and SETd1A SET domains forWDR5 binding, thus destabilizing core complex assembly. This, in turn, leads to down-regulation ofMLL1 and SETd1A
core complex activity.
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ProtKB ID Q8NEZ4), MLL4(2490–2715) (UniProtKB ID
Q9UMN6), SETd1A(1474–1708) (UniProtKB ID O15047),
and SETd1B(1727–1966) (UniProtKB ID Q9UPS6) were sub-
cloned into pGST parallel expression vectors (78) and individ-
ually expressed in Escherichia coli (Rosetta II (DE3) pLysS;
Novagen) and purified as described previously (16). Briefly,
transformed E. coli were grown at 37 °C, shaking at 200–220
rpm for2.5 h until the A600 reached 0.75. Protein expression
was induced with 1 mM isopropyl -D-1-thiogalactopyranoside
for 26 h at 16 °C, shaking at 200–220 rpm. Cell pellets were
resuspended in lysis buffer consisting of Buffer 1 (50 mM Tris
(pH 7.5), 300 mM NaCl, 10% glycerol, 3 mM DTT, 1 M ZnCl2),
supplemented with cOmpleteTM protease inhibitor tablets
(Roche Applied Science) and 0.1 mM PMSF. Cells were
mechanically lysed using a microfluidizer. Proteins were puri-
fied from cleared lysates using a GSTrap-FF column (GE
Healthcare) and eluted over a gradient of 0–10 mM reduced
glutathione. Pooled fractions were dialyzed with three changes
into Buffer 1. Full-lengthWRAD constructs in pHis (78) paral-
lel expression vectors were individually expressed in E. coli
(Rosetta II (DE3) pLysS; Novagen) and purified as described
previously (24). WRAD components were further purified and
buffer-exchanged by gel filtration chromatography (Superdex
200HiLoad 16/60,GEHealthcare) pre-equilibratedwith 20mM
Tris (pH 7.5), 300 mM NaCl, 1 mM tris(2-carboxyethyl)phos-
phine, and 1 M ZnCl2 (Buffer 2). SET1 family mutants were
prepared by site-directedmutagenesis (QuikChange II XL,Agi-
lent). DNA sequencing was performed to verify that only the
intendedmutationwas introduced. Expression andpurification
of SET1 family mutants was carried out as described above.
Methyltransferase Assays
MLL Core ComplexWinMotif Mutants
Histone H3 methyltransferase assays were performed by
incubating GST-tagged SET domains (wild type or Win motif
mutants) with a stoichiometric amount of WRAD (3 M final),
1 Ci of [3H]AdoMet (PerkinElmer Life Sciences), and 100 M
histoneH3 peptides that were unmodified or previouslymono-
or dimethylated at H3K4 in Assay Buffer (50 mM Tris, pH 8.5,
200 mM NaCl, 5 mM MgCl2, 5% glycerol) at 15 °C for 6 h. 15 °C
was chosen as the incubation temperature due to SET domain
instability at higher temperatures.4 Reactions were quenched
with SDS-loading buffer and separated by SDS-PAGE using a
4–12% BisTris gel (Life Technologies) run at 200 V for 30 min.
The gels were enhanced at room temperature for 30 min
(Enlightning, PerkinElmer Life Sciences) and then dried for
2.5 h at 72 °C under constant vacuum. The dried gels were
exposed to film (Eastman Kodak Co. Biomax MS Film) at
80 °C for 4–24 h before developing. Liquid scintillation
counting (LSC) was performed by excising gel bands corre-
sponding to histone H3 peptides, which were dissolved in 750
l of Solvable (PerkinElmer Life Sciences), incubated at room
temperature for 30min, followed by incubation at 50 °C for 3 h.
The solubilized volume of each samplewas transferred to liquid
scintillation vials containing 10 ml of Ultima Gold XL liquid
scintillationmixture (PerkinElmer Life Sciences). Sampleswere
dark-adapted for 1 h and then counted for 5min each with a 2
error cut-off using an all purpose scintillation counter (Beck-
man Coulter).
MLL Core Complex Inhibition byWin6mer
Assay Conditions—MLL core complexes were reconstituted
by mixing purified GST-SET domains (MLL1, MLL4, MLL2,
MLL3, SETd1A, and SETd1B) with WDR5, RbBP5, ASH2L,
and DPY-30 in stoichiometric amounts (GST-SET/W/R/A/D,
1:1:1:1:2). The activity of each core complexwas assessed under
the following conditions: 2MSET1 core complex, 80Mbioti-
nylated H3 substrate peptide, 0.68M [3H]AdoMet (0.5Ci) at
15 °C in Assay Buffer, in a total volume of 10l. Core complex-
or H3 peptide-only reactions incubated with [3H]AdoMet
served as background controls. Reactions were quenched with
167 mM EDTA. Each sample was diluted in 50 l of Buffer 2
containing 0.2 mg/ml BSA and then transferred to 96-well
streptavidin-coated FlashPlatemicroplates (PerkinElmer Life
Sciences). Samples were incubated overnight at 4 °C to allow
binding of the biotinylated H3 peptide to the streptavidin-
coated surface before scintillation counting in a Hidex Sense
microplate reader (LabLogic).
Determination of Linear Ranges—The activity of MLL core
complexes toward H3K4me0, H3K4me1, or H3K4me2 sub-
strate peptides was assayed as described above. Reactions were
quenched at varying time points with 167 mM EDTA and pre-
pared for scintillation counting on Streptavidin FlashPlates. A
plot of counts/min versus timewas constructed, fromwhich the
linear range was determined. Single time points within the lin-
ear range were selected for each SET1 core complex for per-
forming inhibition studies: for H3K4me0: MLL1, MLL2*,
SETd1A, and SETd1B*, 5 min;MLL4, 3 min;MLL3, 15min; for
H3K4me1: MLL1, 5 min; MLL4, 3 min; SETd1A, 15 min;
SETd1B, 45 min; for H3K4me2: SETd1A, 2 h; SETd1B, 1 h
(where an asterisk indicates that 1 M of MLL2 and SETd1B
core complex were used for the H3K4me0 reactions).
Dose-Response Curves—Inhibition studies were performed in
order to determine the efficiency of Win6mer as an MLL core
complex inhibitor. The activity of each MLL core complex
towardH3 substrate peptides was assessed (as described above)
with increasing doses of Win6mer (0, 0.005, 0.05, 0.10, 0.5, 1.0,
2.5, 5.0, 10.0, and 50 M). Reactions were quenched with 167
mM EDTA at the determined time points and prepared for
scintillation counting on streptavidin-coated FlashPlates as
described above.
The activity of SET1 core complexes at each Win6mer con-
centration point was normalized to the activity of the uninhib-
ited core complex to obtain the relative methyltransferase
activity. Inhibition data were plotted as relative methyltrans-
ferase activity versus log[Win6mer] (nM). The Win6mer IC50
values forMLL1 and SETd1A core complexes were determined
by fitting the data to a dose response with variable slope equa-
tion in SigmaPlot 11 as follows.







4 Nilda L. Alicea-Vela´zquez, S. A. Shinsky, D. M. Loh, J.-H. Lee, D. G. Skalnik, and
M. S. Cosgrove, unpublished observation.
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WDR5 Titration intoMLL1- and SETd1A-RAD
GST-MLL1 and GST-SETd1A were mixed with RbBP5,
ASH2L, and DPY-30 in stoichiometric amounts (SET/R/A/D,
1:1:1:2). WDR5 was then titrated into the GST-SET-RADmix-
tures at the following final concentrations: 0.1, 0.5, 0.75, 1.0, 1.5,
2.0, and 5.0 M. Methyltransferase activity toward H3K4me0
substrate was assessed as described under “Assay Conditions.”
The activity ofMLL1- and SETd1A-RADat eachWDR5 con-
centration point was normalized to the activity of the MLL1-
and SETd1A-RAD without WDR5 to obtain the relative meth-
yltransferase activity. Data points were plotted as relative
methyltransferase activity versus log[WDR5] (nM).
MLL SET Domains TreatedwithWin6mer
Isolated SET1 family SET domains (5 M) were incubated
with 1Ci of [3H]AdoMet (PerkinElmer Life Sciences) and 100
M H3K4me0, H3K4me1, or H3K4me2 peptides, with and
without 100 M Win6mer, in Assay Buffer at 15 °C for 8 h.
Reactions were quenched with SDS-loading buffer. Fluorogra-
phy and LSC were carried out as described above.
GST Pull-downs and Immunoblots
GST tagged SET1 family proteins were preincubated with a
stoichiometric amount of purifiedWDR5 (3 M) for 1 h at 4 °C
before being added to prewashed agarose beads coated with
glutathione (Thermo Fisher) and incubated for an additional
2 h at 4 °C with rotation. The beads were washed three times
withBuffer 2 supplementedwith 0.05%TritonX-100 and 0.05%
sodium deoxycholate. The complexes were eluted from beads
by boiling the samples at 95 °C in SDS-loading buffer for 10
min. Samples of the supernatant were run on a 4–12% BisTris
gel (Life Technologies) and either stained with Coomassie Bril-
liant Blue or transferred to a PVDF membrane (Life Technolo-
gies) for 1 h at 30 V.
For pull-down assays using cell extracts, a 3 M concentra-
tion of each GST-tagged SET domain was incubated with 100
g of MCF-7 cell extract for 16 h at 4 °C. Following the initial
incubation, 20 l of a 50:50 slurry of glutathione-agarose beads
was added to each sample and incubated for an additional 2 h at
4 °C. Sampleswerewashed three times in radioimmunoprecipi-
tation buffer. Samples were eluted from beads by boiling the
samples at 95 °C in SDS-loading buffer for 10 min. Samples of
the supernatant were separated on a 4–12% BisTris gel and
transferred to a PVDF membrane at 30 V for 1 h. PVDF mem-
branes were blocked for 1 h with a 5% nonfat milk solution and
then incubated with primary antibody (1:2000) for 1 h at room
temperature. Blots were washed four times and then incubated
with an HRP-conjugated anti-rabbit secondary antibody
(1:5000) for 1 h at room temperature. Blots were washed an
additional four times and then visualized by chemilumines-
cence (Clarity Western, Bio-Rad) on a Bio-Rad ChemiDoc MP
Imager using the chemiluminescence setting.
Co-immunoprecipitation fromMammalian Cells
Inducible human embryonic kidney (T-REx HEK293) cells
were transfected with pcDNA5/TO-FLAG-tagged SETd1A or
pcDNA5/TO-FLAG-tagged SETd1B constructs expressing
either the wild type or Win motif mutants, and stably trans-
fected cells were selected with hygromycin B, as described pre-
viously (1). Following induction with doxycycline, nuclear
extracts were prepared as described (1) and incubated with
anti-FLAG M2 agarose beads (Sigma) for 3 h. Bound proteins
were elutedwith SDS sample buffer after extensivewashing and
analyzed by Western blotting.
ITC
Purified full-length WDR5 and Win6mer peptide were
extensively dialyzed in separate Micro Float-A-Lyzer dialysis
devices, molecular mass cut-off 500–1000 Da (Spectrum Labs)
against sample buffer consisting of 20 mMTris, pH 7.5, 300 mM
NaCl, 1 mM tris(2-carboxyethyl)phosphine, 1 M ZnCl2 buffer.
ITC experiments were carried out at 20 °C using a VP-ITC
microcalorimeter (MicroCal). After an initial delay of 120 s,
Win6mer (200 M) was titrated into the experimental cell con-
taining full-length WDR5 (20 M) over the course of 45 injec-
tions, 5 l each. Reference power was set to 10 cal/s, and
stirring speed was set to 295 rpm. Data were integrated using
NITPIC (79). SEDPHATwas used to fit the integrated data to a
single-site heterogeneous association model, using simulated
annealing andMaxquardt-Levenberg algorithms (80). An auto-
matic confidence interval search with projection method was
applied to estimate the error of the determined thermodynamic
parameters. The confidence interval was set to 2 (95%). The
ITC figure was generated using GUSSI (81).
Crystallization and Structure Determination
A WDR5N construct (residues 23–334) was purified as
described previously (49). The final preparation buffer con-
tained 20mMTris (pH 7.5), 150mMNaCl, 1mM tris(2-carboxy-
ethyl)phosphine, and 1 M ZnCl2. Crystals of the WDR5N-
Win6mer binary complexwere obtained by hanging drop vapor
diffusion. Before crystallization, a 45 mg/ml stock solution of
WDR5Nwas mixed with a 10 mM stock solution ofWin6mer
dissolved in water. The final concentrations of WDR5N and
Win6mer were 350 and 700 M, respectively. The initial crys-
tals were obtained from screeningwith the JCSGCore I Suite in
a condition consisting of 0.1 M sodium citrate, pH 5.6, 20% (v/v)
isopropyl alcohol, and 20% (w/v) PEG 4000. Crystals were
reproduced by manual screening of initial conditions and were
observed in a condition containing 0.1 M sodium citrate, pH 5.6,
15% (v/v) isopropyl alcohol, and 17% (w/v) PEG4000.Hampton
Research Additive Screen was used for further optimization.
The final crystallization condition contained 0.1 M sodium cit-
rate, pH 5.6, 15% 2-propanol, 17% PEG 4000, and 10 mM ATP.
The crystals were flash-frozen in the final mother liquor con-
taining 25% ethylene glycol as a cryoprotectant.
X-ray diffraction data were collected on the F1 beamline at
the Cornell High Energy Synchrotron Source (Ithaca, NY)
using an ADSC Quantum 270 CCD detector. The data set was
indexed, reduced, and scaled with HKL-2000 (82). Data were
originally scaled to a resolution limit of 1.9 Å and then rescaled
to 2.0 Å as the resolution limit cut-off was set to 2.0 Å during
refinement. Data collection statistics of the rescaled data set are
reported in Table 2. Initial phases were obtained by molecular
replacement with Phaser (83) using the coordinates from the
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WDR5 apo-structure (Protein Data Bank code 2H14) (59) as
the search model. After an initial rigid body refinement, auto-
building was performed using ARP/WARP (84). Standard
structural modeling and refinement were performed with Coot
(85) and PHENIX (86), respectively. Refinement statistics are
summarized in Table 2. Validation of the model quality was
assessed with MolProbity (87). All images were made using
CCP4mg (88). Crystallographic software was accessed through
SBGrid (89).
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